Show simple item record

dc.contributor.authorMileshkin, L
dc.contributor.authorEdmondson, R
dc.contributor.authorO'Connell, R
dc.contributor.authorSjoquist, K
dc.contributor.authorAndrews, J
dc.contributor.authorJyothirmayi, R
dc.contributor.authorBeale, P
dc.contributor.authorBonaventura, T
dc.contributor.authorGoh, J
dc.contributor.authorHall, M
dc.contributor.authorClamp, Andrew R
dc.contributor.authorGreen, J
dc.contributor.authorLord, R
dc.contributor.authorAmant, F
dc.contributor.authorAlexander, L
dc.contributor.authorCarty, K
dc.contributor.authorPaul, J
dc.contributor.authorScurry, J
dc.contributor.authorMillan, D
dc.contributor.authorNottley, S
dc.contributor.authorFriedlander, M
dc.date.accessioned2019-06-25T09:32:53Z
dc.date.available2019-06-25T09:32:53Z
dc.date.issued2019en
dc.identifier.citationMileshkin L, Edmondson R, O'Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, et al. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial - ANZGOG 0903. Gynecol Oncol. 2019.en
dc.identifier.pmid31130288en
dc.identifier.doi10.1016/j.ygyno.2019.05.007en
dc.identifier.urihttp://hdl.handle.net/10541/621888
dc.description.abstractBACKGROUND: The clinical benefit rate with aromatase inhibitors and the impact of treatment on quality of life (QOL) in endometrial cancer is unclear. We report the results of a phase 2 trial of anastrozole in endometrial cancer. METHODS: Investigator initiated single-arm, open label trial of anastrozole, 1?mg/d in patients with ER and/or PR positive hormonal therapy naive metastatic endometrial cancer. Patients were treated until progressive disease (PD) or unacceptable toxicity. The primary end-point was clinical benefit (response?+?stable disease) at 3?months. Secondary endpoints include progression-free survival (PFS), quality of life (QOL) and toxicity. RESULTS: Clinical benefit rate in 82 evaluable patients at 3?months was 44% (95% CI: 34-55%) with a best response by RECIST of partial response in 6 pts. (7%; 95% CI: 3-15%). The median PFS was 3.2?months (95% CI: 2.8-5.4). Median duration of clinical benefit was 5.6?months (95% CI: 3.0-13.7). Treatment was well tolerated. Patients who had clinical benefit at 3?months reported clinically significant improvements in several QOL domains compared to those with PD; this was evident by 2?months including improvements in: emotional functioning (39 vs 6%: p?=?0.002), cognitive functioning (45 vs 19%: p?=?0.021), fatigue (47 vs 19%: p?=?0.015) and global health status (42 vs 9%: p?=?0.003). CONCLUSION: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ygyno.2019.05.007en
dc.titlePhase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial - ANZGOG 0903en
dc.typeArticleen
dc.contributor.departmentPeter MacCallum Cancer Centre, The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australiaen
dc.identifier.journalGynecologic Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record